Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial.

Health Qual Life Outcomes · 2017 · PMC5481866 · PMID 28645287

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

approached significanceno p-value reported

The PCHC analysis showed a greater proportion of enzalutamide patients reporting improvement than those receiving placebo (Table 2 ); between group differences were statistically significant ( P < .05) at weeks 13, 25, and 49 and approached significance at week 37.

also in 8,237 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.